NASDAQ:ARAY - Accuray Stock Price, Price Target & More

Get Started

$4.40 -0.55 (-11.11 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$4.40

Today's Range$4.25 - $5.00

52-Week Range$3.60 - $6.15

Volume3.56 million shs

Average Volume775,869 shs

Market Capitalization$432.47 million

P/E Ratio-12.22

Dividend YieldN/A

Beta1.75

About Accuray (NASDAQ:ARAY)

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Equipment

SectorMedical

SymbolNASDAQ:ARAY

CUSIP00439710

Webwww.accuray.com

Phone408-716-4600

Debt

Debt-to-Equity Ratio3.00

Current Ratio1.62

Quick Ratio0.97

Price-To-Earnings

Trailing P/E Ratio-12.22

Forward P/E Ratio-15.17

P/E GrowthN/A

Sales & Book Value

Annual Sales$383.41 million

Price / Sales0.98

Cash FlowN/A

Price / CashN/A

Book Value$0.52 per share

Price / Book8.46

Profitability

EPS (Most Recent Fiscal Year)($0.36)

Net Income$-29,570,000.00

Net Margins-7.00%

Return on Equity-52.91%

Return on Assets-6.25%

Miscellaneous

Employees944

Outstanding Shares85,640,000

Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings results on Monday, April, 30th. The medical equipment provider reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.05. The medical equipment provider earned $99.83 million during the quarter, compared to analysts' expectations of $98.18 million. Accuray had a negative return on equity of 52.91% and a negative net margin of 7.00%. View Accuray's Earnings History.

When is Accuray's next earnings date?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, August, 28th 2018. View Earnings Estimates for Accuray.

What price target have analysts set for ARAY?

6 brokers have issued 1-year price targets for Accuray's stock. Their predictions range from $6.00 to $10.00. On average, they anticipate Accuray's share price to reach $7.40 in the next twelve months. View Analyst Ratings for Accuray.

Are investors shorting Accuray?

Accuray saw a decline in short interest in April. As of April 30th, there was short interest totalling 3,610,718 shares, a decline of 25.4% from the April 13th total of 4,843,303 shares. Based on an average trading volume of 388,878 shares, the days-to-cover ratio is presently 9.3 days. Currently, 4.4% of the company's shares are sold short.

Who are some of Accuray's key competitors?

Some companies that are related to Accuray include iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), MiMedx Group (MDXG), K2M Group (KTWO), CryoLife (CRY), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Cerus (CERS) and AtriCure (ATRC).

Who are Accuray's key executives?

Accuray's management team includes the folowing people:

Mr. Joshua H. Levine, Pres, Chief Exec. Officer & Director (Age 60)
Mr. Kevin Waters, Sr. VP & CFO (Age 41)
Mr. Andrew Kirkpatrick, Sr. VP of Global Operations (Age 55)
Ms. Alaleh Nouri, Sr. VP, Gen. Counsel & Corp. Sec. (Age 39)
Mr. Lionel Hadjadjeba, Sr. VP & Chief Commercial Officer (Age 59)

Has Accuray been receiving favorable news coverage?

Headlines about ARAY stock have trended somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accuray earned a daily sentiment score of 0.22 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 46.34 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.45%), Neuberger Berman Group LLC (5.33%), Russell Investments Group Ltd. (5.18%), Heartland Advisors Inc. (3.71%), Boston Partners (3.07%) and Dimensional Fund Advisors LP (2.19%). Company insiders that own Accuray stock include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Institutional Ownership Trends for Accuray.

Which institutional investors are selling Accuray stock?

ARAY stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Spark Investment Management LLC, Heartland Advisors Inc., Granite Investment Partners LLC, Neuberger Berman Group LLC, UBS Group AG and Lapides Asset Management LLC. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Insider Buying and Selling for Accuray.

Which institutional investors are buying Accuray stock?

ARAY stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Legal & General Group Plc, BlackRock Inc., Global X Management Co. LLC, Dimensional Fund Advisors LP, Boston Partners, Mackay Shields LLC and Algert Global LLC. View Insider Buying and Selling for Accuray.

How do I buy shares of Accuray?

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $4.40.

How big of a company is Accuray?

Accuray has a market capitalization of $432.47 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Accuray employs 944 workers across the globe.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]

MarketBeat Community Rating for Accuray (ARAY)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		233 (Vote Outperform)
Underperform Votes:		190 (Vote Underperform)
Total Votes:		423

MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Accuray (NASDAQ:ARAY) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Accuray in the last 12 months. Their average twelve-month price target is $7.40, suggesting that the stock has a possible upside of 68.18%. The high price target for ARAY is $10.00 and the low price target for ARAY is $6.00. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.33	2.33	2.43	2.50
Ratings Breakdown:	1 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 3 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.40	$7.40	$7.40	$6.60
Price Target Upside:	68.18% upside	51.02% upside	35.78% upside	45.05% upside

Accuray (NASDAQ:ARAY) Consensus Price Target History

Price Target History for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/10/2018	Royal Bank of Canada	Set Price Target	Hold	$6.00	High
12/13/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$6.00	High
11/30/2017	Lake Street Capital	Initiated Coverage	Buy ➝ Buy	$10.00	High
10/27/2017	Cowen	Reiterated Rating	Buy	$9.00	N/A
8/24/2017	BTIG Research	Reiterated Rating	Hold		Medium
8/23/2017	Jefferies Group	Lower Price Target	Buy	$7.00 ➝ $6.00	Low
3/21/2017	Aegis	Reiterated Rating	Buy		Medium
8/18/2016	Morgan Stanley	Set Price Target	Hold	$8.00	N/A

(Data available from 5/26/2016 forward)

Accuray (NASDAQ:ARAY) Earnings History and Estimates Chart

Earnings by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.04)	($0.04)	($0.04)
Q2 2018	1	($0.10)	($0.10)	($0.10)
Q3 2018	1	($0.04)	($0.04)	($0.04)
Q4 2018	1	($0.02)	($0.02)	($0.02)

Accuray (NASDAQ ARAY) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/20/2018		($0.02)					N/A
4/30/2018	Q3 2018	($0.05)	($0.10)	$98.18 million	$99.83 million	View	Listen
1/23/2018	Q2 18	($0.11)	($0.06)	$90.31 million	$100.33 million	View	Listen
10/24/2017	Q1 2018	($0.09)	($0.07)	$88.26 million	$91.00 million	View	N/A
8/22/2017	6/30/2017	($0.01)	($0.06)	$112.00 million	$112.09 million	View	N/A
4/27/2017	Q3 2017	$0.0120	($0.06)	$110.23 million	$97.31 million	View	N/A
1/31/2017	Q217	($0.09)	($0.11)	$93.74 million	$87.50 million	View	Listen
10/27/2016	Q117	($0.10)	($0.12)	$37.34 million	$86.50 million	View	Listen
8/17/2016	Q316	($0.07)	($0.09)	$98.97 million	$95.00 million	View	Listen
4/26/2016	Q316	($0.06)	$0.01	$102.79 million	$105.30 million	View	Listen
1/28/2016	Q216	($0.08)	($0.08)	$101.15 million	$108.90 million	View	Listen
10/29/2015	Q116	($0.14)	($0.12)	$88.60 million	$89.60 million	View	Listen
8/20/2015	Q415	($0.04)	($0.07)	$102.41 million	$101.80 million	View	Listen
4/30/2015	Q315	($0.06)	($0.04)	$102.72 million	$97.50 million	View	Listen
1/27/2015	Q215	($0.08)	($0.13)	$98.87 million	$98.20 million	View	Listen
10/29/2014	Q115	($0.13)	($0.28)	$88.90 million	$82.40 million	View	Listen
8/21/2014	Q414	($0.07)	($0.13)	$92.23 million	$102.00 million	View	Listen
4/30/2014	Q314	($0.16)	($0.06)	$82.00 million	$97.10 million	View	Listen
1/30/2014	Q214	($0.20)	($0.07)	$80.20 million	$93.60 million	View	Listen
11/7/2013	Q114	($0.20)	($0.21)	$79.67 million	$76.60 million	View	Listen
8/27/2013	Q4 2013	($0.20)	($0.20)	$82.29 million	$84.90 million	View	Listen
5/7/2013	Q3 2013	($0.22)	($0.37)	$77.97 million	$70.55 million	View	Listen
2/6/2013	Q2 2013	($0.33)	($0.30)	$74.23 million	$77.80 million	View	Listen
11/7/2012	Q113	($0.22)	($0.23)	$85.41 million	$83.00 million	View	N/A
9/6/2012	Q412	($0.12)	($0.20)	$106.92 million	$100.50 million	View	N/A
5/8/2012		($0.14)	($0.21)			View	N/A
2/8/2012	Q2 2012	($0.19)	($0.10)			View	N/A
11/8/2011		($0.29)	($0.38)			View	N/A
9/19/2011		$0.02	($0.40)			View	N/A
5/5/2011		$0.04	($0.02)			View	N/A
1/27/2011		($0.01)	$0.07			View	N/A
11/8/2010	Q1 2011	($0.07)	($0.08)			View	N/A
8/31/2010	Q4 2010	$0.05	$0.08			View	N/A
5/6/2010	Q3 2010	$0.01	$0.04			View	N/A
2/4/2010	Q2 2010	($0.01)	($0.02)			View	N/A
10/29/2009	Q1 2010	($0.03)	($0.06)			View	N/A
8/24/2009	Q4 2009	$0.03	$0.02			View	N/A
5/5/2009	Q3 2009	$0.02	$0.05			View	N/A
1/29/2009	Q2 2009	$0.02	$0.02			View	N/A
12/18/2008	Q1 2009	$0.02	($0.06)			View	N/A
4/29/2008	Q3 2008	$0.05	$0.01			View	N/A
1/30/2008	Q2 2008	$0.12	$0.04			View	N/A

(Earnings results data provided by Zacks Investment Research)

Accuray (NASDAQ:ARAY) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Accuray (NASDAQ ARAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 83.79%

Insider Trading History for Accuray (NASDAQ:ARAY)

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ ARAY) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/3/2018	Alaleh Nouri	SVP	Sell	2,585	$4.65	$12,020.25	204,483
4/3/2018	Joshua Levine	CEO	Sell	8,675	$4.65	$40,338.75	1,426,753
4/3/2018	Kevin Waters	CFO	Sell	2,997	$4.65	$13,936.05	328,260
12/1/2017	Alaleh Nouri	SVP	Sell	2,166	$4.86	$10,526.76	207,068
12/1/2017	Joshua Levine	CEO	Sell	17,093	$4.86	$83,071.98	1,435,428
12/1/2017	Kevin Waters	CFO	Sell	7,154	$5.06	$36,199.24	335,087
10/4/2017	Kelly Londy	COO	Sell	99,136	$4.24	$420,336.64
11/9/2015	Joshua Levine	CEO	Buy	50,000	$7.12	$356,000.00	1,115,830
2/2/2015	Alaleh Nouri	SVP	Sell	5,164	$7.38	$38,110.32
11/30/2014	Alaleh Nouri	SVP	Sell	268	$6.62	$1,774.16
11/30/2014	Kelly Londy	EVP	Sell	2,273	$6.62	$15,047.26
11/3/2014	Joshua Levine	CEO	Buy	100,000	$6.34	$634,000.00
5/6/2014	Joshua Levine	CEO	Buy	50,000	$8.15	$407,500.00	531,210
2/4/2014	Richard Pettingill	Director	Buy	9,795	$10.33	$101,182.35	43,940
12/4/2013	Jack Goldstein	Director	Sell	7,000	$7.70	$53,900.00	66,237
12/3/2013	Elizabeth Davila	Director	Sell	8,000	$7.74	$61,920.00	77,137
9/4/2013	Darren J Milliken	SVP	Sell	11,002	$6.53	$71,843.06
3/5/2013	Dennis L Winger	Director	Buy	20,000	$4.30	$86,000.00
2/13/2013	Joshua Levine	CEO	Buy	100,000	$4.38	$438,000.00

(Data available from 1/1/2013 forward)

Accuray (NASDAQ ARAY) News Headlines

Source:

Date	Headline
	Why Accuray, Cincinnati Bell, and Chesapeake Energy Slumped Today finance.yahoo.com - May 25 at 5:00 PM
	Accuray Incorporated (ARAY) Expected to Post Quarterly Sales of $108.45 Million www.americanbankingnews.com - May 24 at 8:59 AM
	Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study finance.yahoo.com - May 22 at 8:56 AM
	Brokerages Anticipate Accuray Incorporated (ARAY) Will Post Earnings of -$0.02 Per Share www.americanbankingnews.com - May 22 at 1:16 AM
	Accuray (ARAY) Upgraded to "Hold" at ValuEngine www.americanbankingnews.com - May 18 at 11:48 PM
	Factors of Influence in 2018, Key Indicators and Opportunity within Accuray, Torchmark, Carlisle Companies, CVR ... globenewswire.com - May 15 at 9:31 AM
	Accuray Unveils New Company Website Reflecting Industry-Leading Patient-First Cancer Treatment Innovation and Care www.prnewswire.com - May 15 at 9:31 AM
	Accuray Incorporated (ARAY) Sees Significant Decline in Short Interest www.americanbankingnews.com - May 14 at 1:33 AM
	Accuray Incorporated (ARAY) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - May 13 at 5:35 AM
	Accuray (ARAY) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - May 12 at 5:01 PM
	Mercy Advances Cancer Care in Missouri with Multi-System, Multi-Hospital Agreement for Accuray Radiation Therapy ... www.prnewswire.com - May 9 at 9:08 AM
	Analysts Anticipate Accuray Incorporated (ARAY) Will Post Quarterly Sales of $108.45 Million www.americanbankingnews.com - May 6 at 2:40 AM
	Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules finance.yahoo.com - May 5 at 9:21 AM
	Zacks: Analysts Anticipate Accuray Incorporated (ARAY) Will Post Earnings of -$0.02 Per Share www.americanbankingnews.com - May 4 at 5:21 PM
	Accuray (ARAY) Downgraded by BidaskClub www.americanbankingnews.com - May 3 at 11:21 PM
	FY2018 Earnings Forecast for Accuray Incorporated (ARAY) Issued By Jefferies Group www.americanbankingnews.com - May 3 at 9:52 AM
	Accuray Moves Back From A Spark To A Damp Squib seekingalpha.com - May 1 at 4:41 PM
	BRIEF-Accuray Q3 Loss Per Share $0.10 www.reuters.com - May 1 at 9:07 AM
	Accuray's (ARAY) CEO Josh Levine on Q3 2018 Results - Earnings Call Transcript seekingalpha.com - May 1 at 9:07 AM
	Edited Transcript of ARAY earnings conference call or presentation 30-Apr-18 8:30pm GMT finance.yahoo.com - May 1 at 9:07 AM
	Accuray (ARAY) Announces Quarterly Earnings Results www.americanbankingnews.com - April 30 at 7:08 PM
	Accuray Reports Third Fiscal Quarter Results finance.yahoo.com - April 30 at 4:43 PM
	Accuray: Fiscal 3Q Earnings Snapshot finance.yahoo.com - April 30 at 4:43 PM
	Accuray (ARAY) Upgraded to Hold at BidaskClub www.americanbankingnews.com - April 26 at 1:31 PM
	South Florida Radiation Oncology Treats First Cancer Patients Using Its New CyberKnife® M6™ System www.prnewswire.com - April 24 at 9:02 AM
	Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $98.18 Million www.americanbankingnews.com - April 19 at 2:50 AM
	Accuray Incorporated (ARAY) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 18 at 9:14 AM
	Accuray (ARAY) to Release Quarterly Earnings on Wednesday www.americanbankingnews.com - April 18 at 1:52 AM
	Accuray (ARAY) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 17 at 10:55 PM
	Zacks: Brokerages Expect Accuray Incorporated (ARAY) Will Announce Earnings of -$0.03 Per Share www.americanbankingnews.com - April 17 at 3:19 PM
	Accuray amène les patients au cœur des innovations dans le traitement du cancer à l'ESTRO 37 www.prnewswire.com - April 17 at 7:49 AM
	Accuray (ARAY) Rating Lowered to Strong Sell at Zacks Investment Research www.americanbankingnews.com - April 16 at 9:17 PM
	Accuray (ARAY) Cut to "Sell" at BidaskClub www.americanbankingnews.com - April 15 at 2:21 PM
	Royal Bank of Canada Reiterates "$6.00" Price Target for Accuray (ARAY) www.americanbankingnews.com - April 10 at 12:30 PM
	Accuray To Report Fiscal 2018 Third Quarter Financial Results On April 30, 2018 finance.yahoo.com - April 9 at 9:15 AM
	BidaskClub Downgrades Accuray (ARAY) to Sell www.americanbankingnews.com - April 5 at 10:26 AM
	Accuray (ARAY) Earns Buy Rating from Cowen www.americanbankingnews.com - April 4 at 5:52 PM
	Alaleh Nouri Sells 2,585 Shares of Accuray Incorporated (ARAY) Stock www.americanbankingnews.com - April 3 at 11:05 PM
	Accuray Incorporated (ARAY) CFO Sells $13,936.05 in Stock www.americanbankingnews.com - April 3 at 11:04 PM
	Joshua Levine Sells 8,675 Shares of Accuray Incorporated (ARAY) Stock www.americanbankingnews.com - April 3 at 10:44 PM
	$98.18 Million in Sales Expected for Accuray Incorporated (ARAY) This Quarter www.americanbankingnews.com - April 2 at 2:48 AM
	Accuray Incorporated (ARAY) Expected to Post Earnings of -$0.03 Per Share www.americanbankingnews.com - March 31 at 3:14 PM
	Accuray Radixact Picked by India's Apollo for Cancer Treatment finance.yahoo.com - March 29 at 4:47 PM
	Accuray Radixact Picked by India's Apollo for Cancer Treatment www.zacks.com - March 29 at 9:24 AM
	Accuray Banks on Acquisition & Partnership Amid Competition www.zacks.com - March 28 at 9:19 AM
	Apollo Hospitals in India to Acquire Two Accuray Radixact® Systems www.prnewswire.com - March 28 at 7:51 AM
	Accuray (ARAY) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 27 at 1:51 PM
	Erasmus MC Completes First Step in the Evolution of Online Adaptive Radiation Therapy with the CyberKnife® System finance.yahoo.com - March 27 at 9:26 AM
	Accuray Incorporated (ARAY) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - March 24 at 8:10 AM
	Technical Perspectives on Medical Equipment Stocks -- Accuray, AcelRx Pharma, Aethlon Medical, and CHF Solutions www.bizjournals.com - March 20 at 9:18 AM

Accuray (NASDAQ:ARAY) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Accuray (NASDAQ:ARAY) Income Statement, Balance Sheet and Cash Flow Statement

Accuray (NASDAQ ARAY) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff